EU Breakthrough Device (BtX) Designation: Complete Guide to MDCG 2025-9 and the EMA Pilot Program

What Is the EU Breakthrough Device Framework

Until 2026, the European Union was the last major regulatory jurisdiction without a dedicated pathway for innovative medical devices. The US had the FDA Breakthrough Device Program. Japan had the SAKIGAKE designation and conditional early approval. Australia had TGA priority review. The EU had nothing equivalent.

That changed in December 2025 when the Medical Device Coordination Group (MDCG) published MDCG 2025-9, a guidance document establishing the Breakthrough Device (BtX) framework under the MDR (2017/745) and IVDR (2017/746). Then in April 2026, the European Medicines Agency (EMA) officially launched a pilot program to operationalize the framework, opening the application phase on April 28, 2026.

The BtX framework does not lower safety standards. It reshapes how evidence is generated and assessed across the device lifecycle, offering earlier regulatory engagement, priority review, and structured support — particularly for devices addressing unmet medical needs in life-threatening or irreversibly debilitating conditions.

Eligibility: What Qualifies as a Breakthrough Device

Two Cumulative Criteria

Under MDCG 2025-9, a medical device or IVD qualifies as a breakthrough device (BtX) only if it meets both of the following criteria:

Criterion 1: High Degree of Novelty

The device must be expected to introduce in the EU a high degree of novelty with respect to:

• Device technology (e.g., new materials, nanotechnology, novel sensor platforms)
• Related clinical procedure (e.g., minimally invasive approaches previously not possible)
• Application of the device in clinical practice (e.g., AI-driven diagnostic decisions, closed-loop systems)

Criterion 2: Significant Positive Clinical Impact

The device must be reasonably expected to provide a significant positive clinical impact on patient or public health for life-threatening or irreversibly debilitating diseases or conditions. This means it must either:

• Offer a clinically meaningful improvement in outcomes compared to available alternatives and the state of the art, or
• Address an unmet medical need where no adequate alternatives exist

What Does NOT Qualify

The framework does not apply to:

• Custom-made devices
• In-house devices manufactured by health institutions
• Products listed in Annex XVI without an intended medical purpose
• Incremental improvements without meaningful clinical impact

Novelty alone is insufficient. A device that uses novel technology but does not demonstrably improve patient outcomes for serious conditions will not qualify.

Examples of Potentially Qualifying Technologies

The BtX Designation Process

Step-by-Step Application Flow

Manufacturer submits BtX request to Expert Panel Secretariat
         ↓
Secretariat assigns to relevant Expert Panel
         ↓
Expert Panel reviews against breakthrough criteria
         ↓
Panel aims to issue opinion within 60 days
         ↓
If positive → Device is "BtX designated"
         ↓
Manufacturer can access BtX benefits throughout development
         ↓
Notified Body conformity assessment (with BtX procedural support)
         ↓
CE marking with BtX conditions and enhanced PMCF/PMPF

Request for BtX Status

Manufacturers submit their BtX status request to the Expert Panel Secretariat. The request must include:

1. Device description — what the device is, how it works, and its intended purpose
2. Novelty justification — explanation of what makes the technology novel, with supporting evidence
3. Clinical impact analysis — description of the condition addressed, current standard of care, and how the device improves outcomes
4. State of the art assessment — identification of relevant alternatives and comparison of expected benefits
5. Development stage — where the device is in its development lifecycle (early-stage devices can still qualify)

Expert Panel Review

The relevant Expert Panel reviews the request and aims to issue an opinion within 60 days. The panel evaluates whether both the novelty and clinical impact criteria are met.

Important: BtX designations are not exclusive. Multiple devices with similar intended purposes can receive BtX status if they independently meet the criteria. The designation also remains unaffected if another device with the same intended purpose enters the market.

Designation Notification

Once a positive opinion is reached, the Secretariat notifies the MDCG. The device is then referred to as "BtX designated" and can access the framework's benefits.

What BtX Designation Provides

1. Priority Scientific Advice from EMA Expert Panels

BtX-designated manufacturers can request advice on:

• Clinical development strategy and study design
• Appropriate pre-clinical or clinical data for clinical evaluation
• For IVDs: performance evaluation strategy and appropriate analytical or clinical performance data
• Post-market clinical follow-up (PMCF) or post-market performance follow-up (PMPF) activities

This advice is free during the pilot phase and provides direct access to the same expert panels that advise the European Commission on device policy.

2. Earlier and More Structured Interaction with Notified Bodies

The BtX framework creates a formal legal basis for structured dialogue between manufacturers and Notified Bodies, both pre-submission and post-submission. This includes:

• Pre-submission meetings to discuss evidence strategies
• Agreed evidence generation plans
• Defined milestones and check-ins during assessment

This addresses one of the biggest pain points under the current MDR/IVDR system: the lack of predictable, structured engagement with Notified Bodies during the certification process.

3. Flexibility in Clinical Evidence

BtX designation does not reduce the overall evidence requirement. But it provides flexibility in how evidence is generated:

• Proportionate clinical evidence approaches — recognizing that highly novel devices may face greater uncertainty early in development
• Acceptance of non-clinical data pathways — where appropriate, in silico models and other new approach methodologies can supplement clinical data
• Conditional certification — devices may receive certification with specific conditions linked to defined post-market data generation milestones
• Lifecycle-based evidence generation — the evidence package evolves over time, with post-market studies filling gaps identified during pre-market review

4. Enhanced Regulatory Predictability

For SMEs in particular, the BtX framework offers:

• Earlier clarity on evidence expectations
• Defined interaction points with regulators
• Reduced risk of late-stage surprises during conformity assessment
• Support for navigating complex regulatory landscapes (MDR/IVDR, AI Act, NIS2)

5. Regulatory Sandboxes

The broader MDR/IVDR revision proposes EU or Member State-level regulatory sandboxes that enable supervised testing and data generation for novel technologies. BtX-designated devices are natural candidates for sandbox participation, which can accelerate evidence generation while maintaining safety safeguards.

6. Funding Opportunities

The BtX guidance highlights EU and national funding programs that can support breakthrough device development:

• EU4Health
• Horizon Europe
• EIC Accelerator
• InvestEU

These are complementary to BtX designation — they are not embedded within the designation process but can reduce financial barriers for developers.

Transparency and Post-Market Obligations

BtX designation comes with heightened transparency requirements:

• Labeling — BtX status must be communicated in device labeling
• SSCP/SSP — the Summary of Safety and Clinical Performance (or Summary of Performance for IVDs) must reference BtX designation
• EUDAMED — BtX status must be recorded in the European database on medical devices
• Enhanced PMS — increased post-market surveillance activities, including milestone-based post-market studies, use of registries and real-world data, and more frequent reassessment of benefit-risk by Notified Bodies

The philosophy is clear: greater pre-market flexibility is traded for stronger post-market accountability. Manufacturers must plan for ongoing evidence generation, not one-time approval.

EU BtX vs. FDA Breakthrough Device Program: Key Differences

The EMA Pilot Program (2026–2027)

Key Details

The EMA launched the BtX pilot on April 28, 2026. Key features:

• Duration: Scheduled to run until end of 2027
• Scope: Initially focused on medical devices; IVDs will be included in later phases
• Cost: Scientific advice is free for selected projects during the pilot
• Information session: Held April 24, 2026, ahead of the pilot launch
• Application: Via EMA's medical devices portal

What the Pilot Will Test

The pilot is designed to test the operational framework before the legal provisions in the MDR/IVDR revision take effect. Specifically, it will evaluate:

• How expert panels assess BtX criteria in practice
• The 60-day opinion timeline — is it achievable?
• Quality and usefulness of scientific advice provided
• How structured NB engagement works alongside expert panel input
• Whether conditional certification with post-market milestones is workable

Experience from the pilot will feed into the final legislative framework as the MDR/IVDR revision moves through the European Parliament and Council.

Practical Guide for Manufacturers

Should You Apply?

Consider BtX designation if your device:

• Targets a life-threatening or irreversibly debilitating condition
• Uses genuinely novel technology or applies existing technology in a paradigm-shifting way
• Has preliminary evidence (preclinical or pilot clinical data) suggesting significant clinical benefit
• Would benefit from early expert panel guidance on evidence strategy

Application Checklist

Common Mistakes to Avoid

1. Confusing novelty with clinical impact — both criteria must be independently met. A novel sensor that does not demonstrably improve patient outcomes for serious conditions will not qualify
2. Insufficient state of the art analysis — the expert panel needs a clear picture of current alternatives to assess whether your device offers a significant improvement
3. Applying too late — BtX designation can be sought at an early development stage. Waiting until the device is near market entry misses the opportunity for early scientific advice
4. Underestimating post-market commitments — BtX designation comes with enhanced PMCF/PMPF expectations. Factor these into your development plan from the start

What This Means for IVD Manufacturers

The BtX framework applies to IVDs through the BtIVD (Breakthrough In Vitro Diagnostic) designation. For IVD manufacturers specifically:

• Performance evaluation flexibility — the framework allows for proportionate analytical and clinical performance evidence, recognizing that novel IVDs may not have large patient populations available for clinical studies
• Early panel advice on study design — IVD manufacturers can get expert guidance on performance study design before committing resources
• Connection to CDx pathway — BtIVD designation for companion diagnostics connects to the broader EU framework for personalized medicine
• IVDR revision alignment — the BtX framework operates alongside the proposed IVDR revision, which includes specific provisions for orphan IVDs

Note that during the pilot phase, IVDs will be included in later phases. IVD manufacturers should monitor EMA announcements for the expanded scope timeline.

Key Takeaway

The EU Breakthrough Device framework is the most significant regulatory innovation for European medical device access in a decade. It closes a gap that has pushed innovative technologies toward the US and Japanese markets for years. The EMA pilot program provides a real, operational pathway for manufacturers to engage with — starting now.

For manufacturers with innovative devices targeting serious conditions, the question is not whether to evaluate BtX eligibility, but how quickly to begin the application process.